{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:28:05Z","timestamp":1790692085581,"version":"4.1.0"},"reference-count":10,"publisher":"JLE","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.nephro.2020.03.006","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T11:46:42Z","timestamp":1592567202000},"page":"221-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Syndrome h\u00e9molytique et ur\u00e9mique li\u00e9 au carfilzomib: \u00e9volution favorable sous \u00e9culizumab"],"prefix":"10.1684","volume":"16","author":[{"given":"Catherine","family":"Casiez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Pica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2020.03.006_bib0055","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nephro.2020.03.006_bib0060","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","article-title":"Carfilzomib-induced a HUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1\u00a0deletion","volume":"2","author":"Portuguese","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.nephro.2020.03.006_bib0065","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors-molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nephro.2020.03.006_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical evidence","author":"Gavazzoni","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nephro.2020.03.006_bib0075","series-title":"Retinal Degenerative Diseases","first-page":"237","article-title":"Impairment of the ubiquitin-proteasome pathway in RPE alters the expression of inflammation related genes","author":"Liu","year":"2014"},{"key":"10.1016\/j.nephro.2020.03.006_bib0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney","volume":"127","author":"Keir","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2020.03.006_bib0085","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nature Rev Nephrol"},{"key":"10.1016\/j.nephro.2020.03.006_bib0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: a cause of drug associated thrombotic microangiopathy","volume":"54","author":"Qaqish","year":"2016","journal-title":"Transfusion Apheresis Sci"},{"key":"10.1016\/j.nephro.2020.03.006_bib0095","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2020.03.006_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nefro.2018.02.005","article-title":"Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib","volume":"39","author":"Moliz","year":"2019","journal-title":"Nefrolog\u00eda"}],"container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725520300948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725520300948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2020.03.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:55:39Z","timestamp":1741190139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725520300948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1769725520300948"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2020.03.006","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome h\u00e9molytique et ur\u00e9mique li\u00e9 au carfilzomib: \u00e9volution favorable sous \u00e9culizumab","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2020.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}